Solid Biosciences Inc.

Symbol: SLDB

NASDAQ

10.34

USD

Market price today

  • -2.2412

    P/E Ratio

  • 0.0505

    PEG Ratio

  • 391.48M

    MRK Cap

  • 0.00%

    DIV Yield

Solid Biosciences Inc. (SLDB) Stock Price & Analysis

Shares Outstanding

37.86M

Gross Profit Margin

0.00%

Operating Profit Margin

0.00%

Net Profit Margin

0.00%

Return on Assets

-0.57%

Return on Equity

-0.61%

Return on Capital Employed

-0.69%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Alexander G. Cumbo
Full-time employees:88
City:Cambridge
Address:141 Portland Street
IPO:2018-01-26
CIK:0001707502

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

General Outlook

In simple terms, Solid Biosciences Inc. has 37.861 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -0.570% return, is a testament to Solid Biosciences Inc.'s adeptness in optimizing resource deployment. Solid Biosciences Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.608%. Furthermore, the proficiency of Solid Biosciences Inc. in capital utilization is underscored by a remarkable -0.693% return on capital employed.

Stock Prices

Solid Biosciences Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $9.91, while its low point bottomed out at $8.81. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Solid Biosciences Inc.'s stock market.

Liquidity Ratios

Analyzing SLDB liquidity ratios reveals its financial health of the firm. The current ratio of 893.67% gauges short-term asset coverage for liabilities. The quick ratio (851.69%) assesses immediate liquidity, while the cash ratio (509.85%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio893.67%
Quick Ratio851.69%
Cash Ratio509.85%

Profitability Ratios

The effective tax rate stands at 4.75%, revealing its tax efficiency. The net income per EBT, 97.96%, and the EBT per EBIT, 92.10%, provide insights into its earnings hierarchy.

cards.indicatorcards.value
Effective Tax Rate4.75%
Net Income per EBT97.96%
EBT per EBIT92.10%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 8.94, it details the span from stock purchase to revenue. The 9 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding852
Days of Payables Outstanding251
Payables Turnover1.45

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -4.62, and free cash flow per share, -4.69, depict cash generation on a per-share basis. The cash per share value, 6.06, showcases liquidity position.

cards.indicatorcards.value
Operating Cash Flow per Share-4.62
Free Cash Flow per Share-4.69
Cash per Share6.06
Free Cash Flow to Operating Cash Flow Ratio1.02
Cash Flow Coverage Ratio-3.59
Short Term Coverage Ratio-40.52
Capital Expenditure Coverage Ratio-62.17
Dividend Paid and Capex Coverage Ratio-62.17

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 15.92%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.21, we discern the balance between debt and equity financing. The long-term debt to capitalization, 15.92%, and total debt to capitalization, 17.20%, ratios shed light on its capital structure. An interest coverage of 53.19 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio15.92%
Debt Equity Ratio0.21
Long Term Debt to Capitalization15.92%
Total Debt to Capitalization17.20%
Interest Coverage53.19
Cash Flow to Debt Ratio-3.59
Company Equity Multiplier1.30

Per Share Data

Net income per share, -4.83, reflects the portion of profit attributed to each share. The book value per share, 6.36, represents the net asset value distributed per share, while the tangible book value per share, 6.36, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-4.83
Book Value Per Share6.36
Tangible Book Value Per Share6.36
Shareholders Equity Per Share6.36
Interest Debt Per Share1.32
Capex Per Share-0.08

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -100.00%, indicates top-line expansion, while the gross profit growth, -145.39%, reveals profitability trends. EBIT growth, 2.01%, and operating income growth, 2.01%, offer insights into operational profitability progression. The net income growth, -46.57%, showcases bottom-line expansion, and the EPS growth, 37.27%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-100.00%
Gross Profit Growth-145.39%
EBIT Growth2.01%
Operating Income Growth2.01%
Net Income Growth-46.57%
EPS Growth37.27%
EPS Diluted Growth37.27%
Weighted Average Shares Growth133.60%
Weighted Average Shares Diluted Growth133.60%
Operating Cash Flow Growth3.88%
Free Cash Flow Growth5.24%
10-Year Operating CF Growth per Share-44.46%
5-Year Operating CF Growth per Share85.04%
3-Year Operating CF Growth per Share71.02%
10-Year Net Income Growth per Share2.91%
5-Year Net Income Growth per Share85.68%
3-Year Net Income Growth per Share81.45%
10-Year Shareholders Equity Growth per Share112.08%
5-Year Shareholders Equity Growth per Share-88.73%
3-Year Shareholders Equity Growth per Share-83.33%
Asset Growth-36.62%
Book Value per Share Growth-74.42%
Debt Growth-7.99%
R&D Expense Growth-2.37%
SGA Expenses Growth-13.05%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 74,337,802.98, captures the company's total value, considering both debt and equity. Income quality, 0.98, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value74,337,802.98
Income Quality0.98
Capex to Operating Cash Flow1.61%
Capex to Depreciation-58.70%
Graham Number26.29
Return on Tangible Assets-58.21%
Graham Net Net4.28
Working Capital115,217,000
Tangible Asset Value126,481,000
Net Current Asset Value91,276,000
Average Payables2,635,000
Days Payables Outstanding287
ROIC-68.29%
ROE-0.76%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.67, and the price to book ratio, 1.67, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -4.09, and price to operating cash flows, -2.24, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.67
Price to Book Ratio1.67
Price Cash Flow Ratio-2.24
Price Earnings to Growth Ratio0.05
Enterprise Value Multiple-4.31
Price Fair Value1.67
Price to Operating Cash Flow Ratio-2.24
Price to Free Cash Flows Ratio-4.09
Price to Tangible Book Ratio0.97
Enterprise Value Over EBITDA-0.73
EV to Operating Cash Flow-0.79
Earnings Yield-78.64%
Free Cash Flow Yield-78.38%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Solid Biosciences Inc. (SLDB) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -2.241 in 2024.

What is the ticker symbol of Solid Biosciences Inc. stock?

The ticker symbol of Solid Biosciences Inc. stock is SLDB.

What is company IPO date?

IPO date of Solid Biosciences Inc. is 2018-01-26.

What is company current share price?

Current share price is 10.340 USD.

What is stock market cap today?

The market cap of stock today is 391480672.000.

What is PEG ratio in 2024?

The current 0.050 is 0.050 in 2024.

What is the number of employees in 2024?

In 2024 the company has 88.